Innovation Pharmaceuticals Inc
OTC:IPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nila Infrastructures Ltd
NSE:NILAINFRA
|
IN |
Innovation Pharmaceuticals Inc
Other Current Assets
Innovation Pharmaceuticals Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innovation Pharmaceuticals Inc
OTC:IPIX
|
Other Current Assets
$76k
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$6.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$4.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$853.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
23%
|
CAGR 10-Years
21%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$1.2B
|
CAGR 3-Years
43%
|
CAGR 5-Years
50%
|
CAGR 10-Years
22%
|
|
Innovation Pharmaceuticals Inc
Glance View
Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The firm is engaged in developing therapies with anti-inflammatory, antibiotic, antiviral, dermatology and oncology applications. The firm owns the right to numerous drug compounds, including Brilacidin, its lead drug in a class of compounds known as defensin-mimetics and Kevetrin (thioureidobutyronitrile), which is its lead anti-cancer compound. The firm's clinical trials focused on evaluating its drug candidates, including Kevetrin for the treatment of cancers and Brilacidin for treatments of Acute Bacterial Skin and Skin Structure Infection (ABSSSI), prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative colitis. The firm is focused on developing small molecule therapies to treat diseases in the areas of inflammatory diseases, cancer, dermatology and anti-infectives.
See Also
What is Innovation Pharmaceuticals Inc's Other Current Assets?
Other Current Assets
76k
USD
Based on the financial report for Sep 30, 2023, Innovation Pharmaceuticals Inc's Other Current Assets amounts to 76k USD.
What is Innovation Pharmaceuticals Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
14%
Over the last year, the Other Current Assets growth was -38%. The average annual Other Current Assets growth rates for Innovation Pharmaceuticals Inc have been 1% over the past three years , 5% over the past five years , and 14% over the past ten years .
